It targets CD38-expressing myeloma cells via immune-mediated mechanisms (CDC, ADCC, ADCP) and direct apoptosis, while also influencing CD38-positive immune cells such as Bregs, myeloid-derived suppressor cells, and a recently identified immunosuppressive CD38+ Treg subset. Here, CD38 is linked to plasma cell myeloma.